Inflammatory gene expression in monocytes of patients with schizophrenia: overlap and difference with bipolar disorder. A study in naturalistically treated patients.

Accumulating evidence indicates an activated inflammatory response system as a vulnerability factor for schizophrenia (SZ) and bipolar disorder (BD). We aimed to detect a specific inflammatory monocyte gene expression signature in SZ and compare such signature with our recently described inflammatory monocyte gene signature in BD. A quantitative-polymerase chain reaction (Q-PCR) case-control gene expression study was performed on monocytes of 27 SZ patients and compared to outcomes collected in 56 BD patients (all patients naturalistically treated). For Q-PCR we used nine 'SZ specific genes' (found in whole genome analysis), the 19 BD signature genes (previously found by us) and six recently described autoimmune diabetes inflammatory monocyte genes. Monocytes of SZ patients had (similar to those of BD patients) a high inflammatory set point composed of three subsets of strongly correlating genes characterized by different sets of transcription/MAPK regulating factors. Subset 1A, characterized by ATF3 and DUSP2, and subset 1B, characterized by EGR3 and MXD1, were shared between BD and SZ patients (up-regulated in 67% and 51%, and 34% and 41%, respectively). Subset 2, characterized by PTPN7 and NAB2 was up-regulated in the monocytes of 62% BD, but down-regulated in the monocytes of 48% of SZ patients. Our approach shows that monocytes of SZ and BD patients overlap, but also differ in inflammatory gene expression. Our approach opens new avenues for nosological classifications of psychoses based on the inflammatory state of patients, enabling selection of those patients who might benefit from an anti-inflammatory treatment.

[1]  B. Winblad,et al.  The antidepressant and antiinflammatory effects of rolipram in the central nervous system. , 2006, CNS drug reviews.

[2]  F. Watzinger,et al.  Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program , 2003, Leukemia.

[3]  J. Rybakowski Antiviral and immunomodulatory effect of lithium. , 2000, Pharmacopsychiatry.

[4]  Z. Herman,et al.  Cytokines in schizophrenia and the effects of antipsychotic drugs , 2006, Brain, Behavior, and Immunity.

[5]  P. Hurlin,et al.  The MAX-interacting transcription factor network. , 2006, Seminars in cancer biology.

[6]  N. Andreasen,et al.  COMPREHENSIVE ASSESSMENT OF SYMPTOMS AND HISTORY (CASH) , 2000 .

[7]  Elvira Bramon,et al.  The common genetic liability between schizophrenia and bipolar disorder: A review. , 2001, Current psychiatry reports.

[8]  R. Kahn,et al.  Is Autoimmune Thyroiditis Part of the Genetic Vulnerability (or an Endophenotype) for Bipolar Disorder? , 2007, Biological Psychiatry.

[9]  Marcel J. T. Reinders,et al.  Maximum significance clustering of oligonucleotide microarrays , 2005, 2005 IEEE Computational Systems Bioinformatics Conference - Workshops (CSBW'05).

[10]  Huriya Beyan,et al.  Distinct Monocyte Gene-Expression Profiles in Autoimmune Diabetes , 2008, Diabetes.

[11]  Shaunta' D Martina,et al.  Cilomilast: Orally Active Selective Phosphodiesterase-4 Inhibitor for Treatment of Chronic Obstructive Pulmonary Disease , 2006, The Annals of pharmacotherapy.

[12]  R. S. Smith,et al.  The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. , 1995, Medical hypotheses.

[13]  W. Nolen,et al.  A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. , 2008, Archives of general psychiatry.

[14]  T. Pollmächer,et al.  Effects of antipsychotic drugs on cytokine networks. , 2000, Journal of psychiatric research.

[15]  J. Stockman,et al.  Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study , 2010 .

[16]  A. Gottlieb,et al.  Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial , 2006, The Lancet.

[17]  Kenneth G. C. Smith,et al.  Microarray analysis of human leucocyte subsets: the advantages of positive selection and rapid purification , 2007, BMC Genomics.

[18]  S. Akhondzadeh,et al.  Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial , 2007, Schizophrenia Research.

[19]  Å. Lernmark,et al.  A high prevalence of organ-specific autoimmunity in patients with bipolar disorder , 2004, Biological Psychiatry.

[20]  H. Möller,et al.  The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine , 2006, Molecular Psychiatry.

[21]  J. Powell,et al.  Opposing regulation of T cell function by Egr‐1/NAB2 and Egr‐2/Egr‐3 , 2008, European journal of immunology.

[22]  J. D. Engel,et al.  The world according to Maf. , 1997, Nucleic acids research.

[23]  R. Eisenman,et al.  A switch from Myc:Max to Mad:Max heterocomplexes accompanies monocyte/macrophage differentiation. , 1993, Genes & development.

[24]  N. Wray,et al.  Association between the TRAX/DISC locus and both bipolar disorder and schizophrenia in the Scottish population , 2005, Molecular Psychiatry.

[25]  J. V. van Dongen,et al.  Wnt Target Genes Identified by DNA Microarrays in Immature CD34+ Thymocytes Regulate Proliferation and Cell Adhesion1 , 2004, The Journal of Immunology.

[26]  H. Möller,et al.  COX-2 inhibition as a treatment approach in schizophrenia: Immunological considerations and clinical effects of celecoxib add-on therapy , 2004, European Archives of Psychiatry and Clinical Neuroscience.

[27]  N C Andreasen,et al.  The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology. , 1992, Archives of general psychiatry.

[28]  A J Rush,et al.  The Stanley Foundation Bipolar Treatment Outcome Network. II. Demographics and illness characteristics of the first 261 patients. , 2001, Journal of affective disorders.

[29]  G. Zunta-Soares,et al.  Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double‐blind, randomized, placebo‐controlled study , 2008, Human psychopharmacology.

[30]  W. Nolen,et al.  A relative resistance of T cells to dexamethasone in bipolar disorder. , 2006, Bipolar disorders.

[31]  O. Mors,et al.  Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. , 2006, The American journal of psychiatry.

[32]  M. Tadri,et al.  Psychiatrie , 2021, Revue Médicale Suisse.

[33]  V. Blank Small Maf proteins in mammalian gene control: mere dimerization partners or dynamic transcriptional regulators? , 2008, Journal of molecular biology.

[34]  N. Craddock,et al.  Diagnosis of functional psychoses: time to face the future , 2009, The Lancet.

[35]  Anja Vaskinn,et al.  The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: a comparative study. , 2007, The Journal of clinical psychiatry.

[36]  N. Craddock,et al.  Rethinking psychosis: the disadvantages of a dichotomous classification now outweigh the advantages. , 2007, World psychiatry : official journal of the World Psychiatric Association.

[37]  H. Steinbusch,et al.  Effect of the COX-2 Inhibitor Celecoxib on Behavioural and Immune Changes in an Olfactory Bulbectomised Rat Model of Depression , 2007, Neuroimmunomodulation.

[38]  Rybakowski Jk Antiviral and immunomodulatory effect of lithium. , 2000 .